Socio-economic status and the therapeutic effectiveness of antihypertensive treatment – the design of the LEO study

References

• Thamm M. Blutdruck in Deutschland - aktueller Status und Trends. Gesundheitswesen 1999;61(Spec No):S90–S93
   Google Scholar
• Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004;22:479–86
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. J Am Med Assoc 2003;289: 2363–9
   Google Scholar
• ESH/ESC. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011–53
   Google Scholar
• Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. J Am Med Assoc 2003;289:2534–44
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10–7
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–23
   PubMed Web of Science ®Google Scholar
• Takala J, Kumpusalo E. Verenpainepotilas terveyskeskuksessa: hoidossa yhä parantamisen varaa. Suom Lääkäril 2001;56:269–74
   Google Scholar
• Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001;19:S41–S48
   Google Scholar
• Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3: 283–91, 318
   Google Scholar
• Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049–51
   PubMed Web of Science ®Google Scholar
• Mayer Jr O, Simon J, Heidrich J, et al. Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy. J Epidemiol Community Health 2004;58:47–52
   PubMed Web of Science ®Google Scholar
• Rutledge T, Reis SE, Olson M, et al. Socioeconomic status variables predict cardiovascular disease risk factors and prospective mortality risk among women with chest pain. The WISE Study. Behav Modif 2003;27:54–67
   PubMed Web of Science ®Google Scholar
• Bachmann MO, Eachus J, Hopper CD, et al. Socio-economic inequalities in diabetes complications, control, attitudes and health service use: a cross-sectional study. Diabetic Med 2003;20:921–9
   PubMed Web of Science ®Google Scholar
• Marmot MG, McDowall ME. Mortality decline and widening social inequalities. Lancet 1986;2:274–6
   PubMed Web of Science ®Google Scholar
• Pekkanen J, Uutela A, Valkonen T, et al. Coronary risk factor levels: differences between educational groups in 1972–87 in eastern Finland. J Epidemiol Community Health 1995;49:144–9
   PubMed Web of Science ®Google Scholar
• Schneider S, Mohnen S, Schiltenwolf M. ‘Are rich people healthier?’ – representative epidemiological data on socioeconomic group-specific disease prevalences among adults in Germany. Dtsch Med Wochenschr 2006;131:1998–2003
   Google Scholar
• Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881–4
   PubMed Web of Science ®Google Scholar
• Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol 1997;13:914–20
   PubMed Web of Science ®Google Scholar
• Fincke BG, Miller DR, Spiro 3rd A. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med 1998;13:182–5
   Google Scholar
• Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997;95:1085–90
   Google Scholar
• Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. New Engl J Med 1998;339:1957–63
   PubMed Web of Science ®Google Scholar
• Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413–20
   PubMed Web of Science ®Google Scholar
• Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000;160:2281–6
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. J Am Med Assoc 2003;289:2560–71
   PubMed Web of Science ®Google Scholar
• Martin DJ, Garske JP, Davis MK. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. Journal Consult Clin Psychol 2000;68:438–50
   Google Scholar
• Neuwirth ZE. Physician empathy – should we care? Lancet 1997;350:606
   PubMed Web of Science ®Google Scholar
• Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446–57[discussion 24–5]
   Google Scholar
• Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23:1999–2010
   PubMed Web of Science ®Google Scholar
• Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005;14:795–803
   PubMed Web of Science ®Google Scholar
• Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569–75
   PubMed Web of Science ®Google Scholar
• Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001;19:S41–S48
   Google Scholar
• Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3: 283–91, 318
   Google Scholar
• Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049–51
   PubMed Web of Science ®Google Scholar
• Liberatos P, Link BG, Kelsey JL. The measurement of social class in epidemiology. Epidemiologic reviews 1988;10:87–121
   PubMed Web of Science ®Google Scholar
• Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993;88:1973–98
   PubMed Web of Science ®Google Scholar
• Helmert U, Herman B, Joeckel KH, et al. Social class and risk factors for coronary heart disease in the Federal Republic of Germany. Results of the baseline survey of the German Cardiovascular Prevention Study (GCP). J Epidemiol Community Health 1989;43:37–42
   PubMed Web of Science ®Google Scholar
• Helmert U, Mielck A, Classen E. Social inequities in cardiovascular disease risk factors in East and West Germany. Soc Sci Med 1992;35:1283–92
   Google Scholar
• Marotta T, Viola S, Ferrara F, Ferrara LA. Improvement of cardiovascular risk profile in an elderly population of low social level: the ICON (Improving Cardiovascular risk profile in Older Neapolitans) study. J Hum Hypertens 2007;21:76–85
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Hemingway H, Poulter NR. Socio-economic status and blood pressure: an overview analysis. J Hum Hypertens 1998;12:91–110
   Google Scholar
• Krupa-Wojciechowska B, Zdrojewski T. Socio-economic factors in the management of hypertension: the Polish experience. J Hypertens 2004;22:661–2
   Google Scholar
• Hypertension Detection and Follow-up Program Cooperative Group. Race, education and prevalence of hypertension. Am J Epidemiol 1977;106:351–61
   Google Scholar
• Schneiderman MA. The proper size of a clinical trial: ‘Grandma’s Strudel’ method. J New Drugs 1964;45:3–11
   Google Scholar
• Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004;26(Suppl A):A28–A32
   Google Scholar
• Dusing R. Adherence to medical treatment. Dtsch Med Wochenschr 2006;131:H28–H30
   PubMedGoogle Scholar
• Zdrojewski T, Pienkowski R, Szynkiewicz M, Krupa-Wojciechowska B. Have rapid socioeconomic changes influenced awareness of blood pressure in Poland? J Hum Hypertens 2001;15:247–53
   Google Scholar